CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the stocks that could 10x over the next 10 years. Piper Sandler boosted its ...

A US patent board last week backed the Broad Institute’s claim to CRISPR use in human and animal cells, not the Nobel winners ...

Any molecular biologist will tell you that genetic engineering is tricky. But up until recently we might be witnessing a new ...

2023 was the year that CRISPR gene-editing sliced its way out of the lab and into the public consciousness—and American medical system. The Food and Drug Administration recently approved the first ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Discover how CRISPR genome editing is revolutionizing medicine. Learn the science of Cas9, current clinical trials, and the ...

CRISPR ended 2023 with a bang. In November, the gene editing tool scored its first clinical approval for treating sickle cell anemia and beta-thalassemia in the United Kingdom. These painful blood ...

Add Yahoo as a preferred source to see more of our stories on Google. Stanford researchers have developed CRISPR-GPT, an AI-powered copilot that guides gene-editing experiments. (CREDIT: Shutterstock) ...

Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that the U.S. Patent and Trademark Office ...

In the never-ending quest to discover previously unknown CRISPR gene-editing systems, researchers have scoured microbes in everything from hot springs and peat bogs to poo and even yogurt. Now, thanks ...

CRISPR recently raised nearly $600 million through a private offering, which weighed down its share price. The company has an ...